All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, March 7, 2021
Home » Topics » Deals and M&A

Deals and M&A
%{topic} RSS Feed RSS

Cancer cells under magnifying glass

CD3 just the ticket as Lilly buys into Merus bispecifics platform in $1.7B immuno-oncology deal

Jan. 19, 2021
By Cormac Sheridan
No Comments
DUBLIN – Merus NV is banking $40 million up front, plus an equity investment of $20 million, under a research collaboration and license agreement with Eli Lilly and Co.’s Loxo Oncology arm to develop up to three CD3-directed bispecific T-cell engager antibodies. Each program also has up to $540 million attached in development and commercialization milestones, taking the total potential value of the deal to $1.68 billion. Merus would also receive tiered royalties on any product sales, ranging, in percentage terms, from mid-single-digits to low-double-digits.
Read More
2020 pandemic illustration

Volume up, value down, but digital tops 2020’s deal-making efforts

Jan. 14, 2021
By Karen Carey
No Comments
The volume of med-tech deals and M&As in 2020 reached impressive levels, well above 2019, primarily due to the demands of a global pandemic, although the disclosed values of those alliances fell dramatically short. Even so, the spotlight that shined on digital health and diagnostics throughout the challenging year has potentially set up the med-tech industry for an influx of attention going forward.
Read More
Kidney illustration

Renalytix and Davita join forces to identify and manage early-stage kidney disease

Jan. 13, 2021
By Annette Boyle
No Comments
Diagnostics innovator Renalytix AI plc and dialysis giant Davita Inc. partnered to develop a program to identify individuals with early-stage kidney disease and improve outcomes for the 37 million Americans with chronic kidney disease (CKD). The companies plan to launch the collaborative effort in three cities in 2021 to build a diverse, real-world evidence dataset as a base for moving forward.
Read More

Evoq captures $240M autoimmune development deal with Amgen

Jan. 13, 2021
By Michael Fitzhugh
No Comments
Evoq Therapeutics LLC, a Michigan-based company developing a new technology for treating autoimmune disease, has signed a new license and collaboration agreement giving Amgen Inc. exclusive rights to selected programs in the area, undisclosed in number and indication. Valued at more than $240 million in up-front and milestone payments, the deal also includes potential royalties on sales of resulting therapies, Evoq said.
Read More
DNA on digital background

Screen savior? KSQ’s CRISPRomics bags major Takeda deal

Jan. 13, 2021
By Randy Osborne
No Comments
KSQ Therapeutics Inc.’s chief scientific officer, Frank Stegmeier, said that the CRISPRomics technology that drew Takeda Pharmaceutical Co. Ltd. to the table allows, “for the first time, genome-scale functional screening [in vivo as well as in vitro] across multiple disease settings. It really takes the guessing game out of your drug target selection.” Working with “an encyclopedia of gene function,” he said, KSQ aims to identify prospects that can have monotherapy activity in PD-1-refractory solid tumors.
Read More

Merck joins SHP2 players in expanded Astex-Taiho deal

Jan. 13, 2021
By Nuala Moran
No Comments
LONDON – Merck & Co. Inc. has become the latest pharma company to in-license a SHP2 small-molecule program, as the rush to find companion pieces for KRAS oncogene inhibitors heats up.
Read More
Deal handshake and arrows sketch on chalkboard

More than $1B in partnering deals keep last year’s momentum going

Jan. 12, 2021
By Lee Landenberger
No Comments
As a virtual 39th J.P. Morgan Annual Healthcare Conference begins, typically one of the biggest events of the year, biopharma dealmaking barreled ahead with five new deals Jan. 11 that could eventually hit $1.04 billion in total.
Read More
Handshake dollar sign

Steris to acquire Cantel Medical for $3.6B

Jan. 12, 2021
By Meg Bryant
No Comments
Steris plc has agreed to buy Cantel Medical Corp. for approximately $3.6 billion, in a cash and stock transaction that unites two key players in the infection prevention space. The combined company offers a number of synergies. Cantel’s medical portfolio is expected to bolster and expand Steris’ endoscopy offerings, with a full-suite of high-level disinfection consumables, capital equipment and services plus single-use accessories.
Read More
Handshake with cityscape and businesspeople

Robust deals hit $197B in 2020; M&As ready to rebound

Jan. 12, 2021
By Karen Carey
No Comments
With several deals and M&As falling within the highest values on record, 2020 turned out to be a solid year for the biopharma industry. Expectations are optimistic moving into 2021, when the U.S. will welcome a new president and its citizens should reach herd immunity from COVID-19.
Read More

Sanofi goes one step Biond checkpoint madness with $1B-plus cancer deal

Jan. 12, 2021
By Randy Osborne
No Comments
Biond Biologics Ltd. co-founder and CEO Tehila Ben-Moshe told BioWorld that “a relatively small group of scientists who are very motivated started with a very basic scientific idea, which we were able to take all the way into clinical trials in four years,” and draw the interest of Paris-based Sanofi SA in a checkpoint inhibitor with multi-cell effects. In its second major deal of the week, Sanofi is pledging $125 million up front and more than $1 billion more in potential development, regulatory and sales-related milestone payments to Biond, of Misgav, Israel.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 … 69 70 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 5.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 5.
  • Coronavirus vaccine/therapeutics illustration

    Tonix looks to the past for the future of COVID-19 vaccines and testing

    BioWorld MedTech
    Tonix Pharmaceuticals Holding Corp. is looking to lessons from tuberculosis and smallpox to guide its future in infectious diseases. The company is developing an...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing